Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat
Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday’s midterm elections, Democrats emerged…
LABU
After a Rough October, Leveraged Biotech ETF Looks to Bounce Back
Biotechnology stocks and exchange traded funds participated in the October broader market swoon, punishing funds such as the Direxion Daily S&P Biotech…
Pharma, Biotech Bull ETFs Leading the Charge
The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few…
5 Big Direxion ETFs Trending This Week
Since 1997, Direxion has been providing investment solutions with their innovative ETFs and 20 years later, they have $13.4 billion worth of…
Big Biotech ETF Can Bounce Back
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping,…
Catalysts Abound for Biotech ETFs
Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech…
Betting Big on Biotech ETFs? Traders Leverage ETFs
With biotechnology stocks and ETFs expected to remain areas of interest throughout 2018, risk-tolerant traders may want to consider examining leveraged ETFs…
Good Reasons to Stick With Biotech ETFs
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, tumbled alongside the broader market in February. In…
Healthcare Dip Could be a Buying Opportunity
The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled…
Biotech ETFs Pop on Celgene, Juno Deal
Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand its cancer treatment…
Adding Some Juice to the Healthcare Trade
Aggressive traders looking to add some excitement and, potentially increased short-term returns, to the healthcare trade have some ideas to consider including…
Biotech Slump Could be a Buying Opportunity
Biotechnology stocks and ETFs are slumping in the fourth quarter. For example, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF…
Biotech Decline Could be a Buying Opportunity
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca:…
Bullish Biotech Bets After Positive Attention
Biotechnology ETFs have been getting plenty of positive attention in recent weeks, a trend that certainly extends to the SPDR S&P Biotech…